Xtl Biopharmaceuticals (XTLB) Return on Sales (2011 - 2024)

Xtl Biopharmaceuticals (XTLB) posted quarterly Return on Sales of 0.04% for Q4 2024, down 538.41% on a QoQ basis from 0.01% in Q3 2018.

Xtl Biopharmaceuticals (XTLB) Return on Sales (2011 - 2024) Analysis & Trends

Xtl Biopharmaceuticals (XTLB) has reported Return on Sales for 7 consecutive years, with 0.04% the latest figure, recorded in Q4 2024.

Quarterly Return on Sales changed N/A year-over-year to 0.04% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 0.01% (changed N/A YoY) and the FY2025 annual result came in at 0.0%, up 3.0% from the prior year.
Return on Sales declined to 0.04% in Q4 2024 per XTLB's latest filing, from 0.01% in the prior quarter.
Over the last five years, Return on Sales for XTLB reached as high as 0.04% in Q4 2024 and fell as low as 0.04% in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Oculis Holding AG	66,801.52 Bn	66,801.23 Bn	-	-
2	Nanobiotix	1,916.61 Bn	1,916.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.65 Bn	466.85 Bn	1.35 Bn	0.00%
5	Vertex Pharmaceuticals	121.94 Bn	114.69 Bn	2.59 Bn	0.00%
6	Regeneron Pharmaceuticals	69.85 Bn	61.09 Bn	3.31 Bn	0.00%
7	Belite Bio	63.06 Bn	63.06 Bn	-	-
8	Argenx Se	55.74 Bn	50.56 Bn	1.41 Bn	0.00%
9	Revolution Medicines	37.48 Bn	37.48 Bn	-	-
10	Xtl Biopharmaceuticals	2.58 Bn	2.58 Bn	-	-

Download Data